- Home
- EDIT vs RGCO Comparison
EDIT vs RGCO Comparison
Compare EDIT & RGCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- RGCO
- Stock Information
- Founded
- EDIT 2013
- RGCO 1912
- Country
- EDIT United States
- RGCO United States
- Employees
- EDIT N/A
- RGCO N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- RGCO Oil & Gas Production
- Sector
- EDIT Health Care
- RGCO Utilities
- Exchange
- EDIT Nasdaq
- RGCO Nasdaq
- Market Cap
- EDIT 241.9M
- RGCO 221.2M
- IPO Year
- EDIT 2016
- RGCO N/A
- Fundamental
- Price
- EDIT $2.69
- RGCO $21.79
- Analyst Decision
- EDIT Buy
- RGCO
- Analyst Count
- EDIT 12
- RGCO 0
- Target Price
- EDIT $5.40
- RGCO N/A
- AVG Volume (30 Days)
- EDIT 1.3M
- RGCO 15.6K
- Earning Date
- EDIT 11-03-2025
- RGCO 11-12-2025
- Dividend Yield
- EDIT N/A
- RGCO 3.81%
- EPS Growth
- EDIT N/A
- RGCO 5.90
- EPS
- EDIT N/A
- RGCO 1.32
- Revenue
- EDIT $38,901,000.00
- RGCO $94,120,500.00
- Revenue This Year
- EDIT N/A
- RGCO $14.48
- Revenue Next Year
- EDIT N/A
- RGCO $2.11
- P/E Ratio
- EDIT N/A
- RGCO $16.45
- Revenue Growth
- EDIT N/A
- RGCO 12.04
- 52 Week Low
- EDIT $0.91
- RGCO $19.06
- 52 Week High
- EDIT $4.12
- RGCO $24.20
- Technical
- Relative Strength Index (RSI)
- EDIT 51.07
- RGCO 48.02
- Support Level
- EDIT $2.56
- RGCO $21.54
- Resistance Level
- EDIT $2.84
- RGCO $22.48
- Average True Range (ATR)
- EDIT 0.17
- RGCO 0.59
- MACD
- EDIT 0.00
- RGCO -0.06
- Stochastic Oscillator
- EDIT 58.82
- RGCO 28.83
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About RGCO RGC Resources Inc.
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.